Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Tapering of Pembrolizumab in NSCLC
NCT04909684Phase 3Unknown
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2020
- Primary completion
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in non-small cell lung carcinoma (NSCLC), sponsored by Radboud University Medical Center. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT04909684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04909684.